{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:10:56Z","timestamp":1779286256892,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:58:48Z","timestamp":1774933128000},"page":"514-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase I Single and Multiple Ascending Dose, Food Effect Study of the Safety, Tolerability and Pharmacokinetics of SAL0133 in Healthy Participants"],"prefix":"10.1016","volume":"48","author":[{"given":"Qi","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengmei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8796-701X","authenticated-orcid":false,"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.017_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1355097","article-title":"Global trends in COVID-19 incidence and case fatality rates (2019-2023): a retrospective analysis","volume":"12","author":"Du","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0002","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1016\/S2666-5247(23)00146-5","article-title":"Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study","volume":"4","author":"Lin","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/joim.13478","article-title":"Advances in the omicron variant development","volume":"292","author":"Vitiello","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20032150","article-title":"Outcomes of elderly patients hospitalized with the SARS-CoV-2 omicron B.1.1.529 variant: a systematic review","volume":"20","author":"Fericean","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0006","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1021\/acs.jmedchem.1c00566","article-title":"Discovery and mechanism of SARS-CoV-2 main protease inhibitors","volume":"65","author":"Huff","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0007","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0008","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0009","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic response and safety of ibuzatrelvir, a novel SARS-CoV-2 antiviral, in adults with COVID-19","volume":"80","author":"Mortezavi","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0011","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0012","unstructured":"<number>12.<\/number>U.S. Department of Health and Human Services FaDAF. Food-Effect Bioavailability and Fed Bioequivalence Studies: Guidance for Industry In: (FDA) USFaDA, ed. Rockville, MD 2002."},{"key":"10.1016\/j.clinthera.2026.03.017_bib0013","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0014","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02850186","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers","volume":"22","author":"Ullmann","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0017","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","article-title":"Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics","volume":"87","author":"Wacher","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0018","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1038\/s41598-021-85174-w","article-title":"Enteric reabsorption processes and their impact on drug pharmacokinetics","volume":"11","author":"Ibarra","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106598","article-title":"A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects","volume":"191","author":"Yang","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0021","series-title":"A Phase 1 Study of S-217622 in Healthy Adult Participants","year":"2022"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0022","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/13892002113149990002","article-title":"Systematic evaluation of dose accumulation studies in clinical pharmacokinetics","volume":"14","author":"Li","year":"2013","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0023","series-title":"Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System","year":"2000"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0024","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40261-021-01078-7","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of AZD5718, an oral 5-lipoxygenase-activating protein (FLAP) inhibitor, in healthy Japanese male subjects","volume":"41","author":"Kn\u00f6chel","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2026.03.017_bib0025","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:01Z","timestamp":1779284101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000792"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Single and Multiple Ascending Dose, Food Effect Study of the Safety, Tolerability and Pharmacokinetics of SAL0133 in Healthy Participants","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}